Clinical efficacy and safety of amifostine on elderly patients with acute leukemia receiving chemotherapy
10.13699/j.cnki.1001-6821.2015.03.010
- VernacularTitle:氨磷汀对老年急性白血病化疗患者的疗效与安全性评价
- Author:
Zhi-Gang QU
1
;
Bing-Mu FANG
;
Guang-Li MA
;
Jin-Hong JIANG
;
Qiao-Lei ZHANG
;
Xiao-Qiu WANG
;
Xiao-Li WANG
;
Yong-Hua LIU
Author Information
1. 丽水市人民医院 血液科
- Keywords:
amifostine;
hematologic malignancy;
elderly;
chemotherapy
- From:
The Chinese Journal of Clinical Pharmacology
2015;(3):190-192
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of amifostine on elderly acute leukemia patients receiving chemotherapy.Methods Fifty-eight patients with acute leukemia treated with chemo-therapy and amifostine were recruited in this study and then divided into two groups, 28 cases in elderly group (≥60 years) and 30 cases in control group (<60 years).All the patients were given amifostine 600 mg· m-2 through intravenous injection 15 to 30 minutes prior chemothe-rapy for 4 cycles.The data of the influence of amifostine on chemotherapy-induced adverse reactions as well as patients′blood pressure were compared in two groups.Results There was no statistical difference in incidence rates of chemotherapy -induced adverse reactions in two groups (P>0.05).After chemotherapy, there were 82 (80.4%) and 102 (80.3%) cases showing decreasing systolic blood pressure in elderly group and control group, respectively, and 71 ( 69.6%) and 83 ( 62.9%) cases showing decreasing diastolic blood pressure ( P >0.05).Conclusion The application of amifostine on elderly acute leukemia patients who has received chemotherapy is safe and could relieve chemotherapy-induced adverse reactions.
